Injection Drug Use and HIV/AIDS
- HIV/AIDS, Injection Drug Use, and Race in the US
- Supervised Consumption Spaces
- Syringe Service Programs
- Hepatitis C and Injection Drug Use
- Persons In The US Living with Diagnosed HIV Infection Ever Classified as Stage 3 (AIDS), by Transmission Method
Page last updated June 9, 2020 by Doug McVay, Editor/Senior Policy Analyst.
31. Cases of AIDS, Cumulative Through 2007
"Through 2007, a total of 1,030,832 persons in the United States and dependent areas had been reported as having AIDS (Table 16). Three states (California, Florida, and New York) reported 43% of the cumulative AIDS cases and 36% of AIDS cases reported to CDC in 2007. In the 50 states and the District of Columbia, the rate of reported AIDS cases in 2007 was 12.4 per 100,000 population. When the U.S. dependent areas were included, the rate of reported AIDS cases ranged from zero per 100,000 (American Samoa, Guam, and the Northern Mariana Islands) to 148.1 per 100,000 (District of Columbia)."
Centers for Disease Control and Prevention, "HIV/AIDS Surveillance Report, 2007," Vol. 19. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009: p. 9.
32. Cost Effectiveness of Harm Reduction
"Prevention of HIV is also cheaper than treatment of HIV/AIDS. For example, in Asia it is estimated that the comprehensive package of HIV-related harm reduction interventions costs $39 per disability-adjusted life-year saved,14 whereas antiretroviral treatment costs approximately $2,000 per life-year saved. Such figures demonstrate that harm reduction is a low-cost, high-impact intervention."
"Three cents a day is not enough: Resourcing HIV-related Harm Reduction on a global basis," International Harm Reduction Association (London, United Kingdom: 2010), p. 12.
33. Global Estimated Drug-Related Mortality, 2011
"UNODC estimates that there were between 102,000 and 247,000 drug-related deaths in 2011, corresponding to a mortality rate of between 22.3 and 54.0 deaths per million population aged 15-64. This represents between 0.54 per cent and 1.3 per cent of mortality from all causes globally among those aged 15-64.20 The extent of drug-related deaths has essentially remained unchanged globally and within regions."
UNODC, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6), p. 10.
34. Global Expenditures
"Global expenditure on HIV/AIDS has increased substantially in the last decade, with total annual resources from all sources reaching over $11.3 billion in 2007 and $13.7 billion in 2008.37 Most of these resources are destined for low and middle income countries and include the expenditure allocated to HIV/AIDS prevention, care, treatment and support."
"The Global Fund [to Fight AIDS, Tuberculosis and Malaria]’s annual HIV/AIDS disbursement was approximately $1 billion in 2007,39 $1.6 billion in 2008 and $2.8 billion in 2009.40 From 2002 to 2009 the Global Fund has approved a total grant amount of $10 billion for HIV/AIDS prevention, treatment and care. For the 2008 to 2010 biennium, $9.7 billion has been pledged to the Global Fund for all activities by countries and private donors."41
"The total resources made available for HIV/AIDS increased from $7.9 billion in 2005 to $13.8 million in 2008. Nevertheless, there continues to be a resource gap. UNAIDS estimates that overall the funding needed in 2007 was $18 billion,45 indicating that resources need to be increased by about 60%."
"Three cents a day is not enough: Resourcing HIV-related Harm Reduction on a global basis," International Harm Reduction Association (London, United Kingdom: 2010), pp. 19-21.
35. Estimated Global Spending on AIDS
"UNAIDS estimates that the total global resources needed for HIV/AIDS for the period 2009 to 2013 is almost $200 billion to achieve universal access by 2010, and $140 billion for a slower scale-up to achieve universal access by 2015.83
"Three cents a day is not enough: Resourcing HIV-related Harm Reduction on a global basis," International Harm Reduction Association (London, United Kingdom: 2010), pp. 38-39.